NO20081213L - Mikropartikkelsammensetninger av topoisomerase I-inhibitoren 7-tert-butoksyiminometylcamptothecin - Google Patents

Mikropartikkelsammensetninger av topoisomerase I-inhibitoren 7-tert-butoksyiminometylcamptothecin

Info

Publication number
NO20081213L
NO20081213L NO20081213A NO20081213A NO20081213L NO 20081213 L NO20081213 L NO 20081213L NO 20081213 A NO20081213 A NO 20081213A NO 20081213 A NO20081213 A NO 20081213A NO 20081213 L NO20081213 L NO 20081213L
Authority
NO
Norway
Prior art keywords
butoxyiminomethylcamptothecin
topoisomerase
inhibitor
tert
microparticle compositions
Prior art date
Application number
NO20081213A
Other languages
English (en)
Norwegian (no)
Inventor
Oskar Kalb
Wolfgang Wirth
Isabel Ottinger
Walter Stebler
Agnes Taillardat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081213(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081213L publication Critical patent/NO20081213L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20081213A 2005-08-10 2008-03-07 Mikropartikkelsammensetninger av topoisomerase I-inhibitoren 7-tert-butoksyiminometylcamptothecin NO20081213L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10
PCT/EP2006/065160 WO2007017514A1 (en) 2005-08-10 2006-08-08 Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin

Publications (1)

Publication Number Publication Date
NO20081213L true NO20081213L (no) 2008-05-13

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081213A NO20081213L (no) 2005-08-10 2008-03-07 Mikropartikkelsammensetninger av topoisomerase I-inhibitoren 7-tert-butoksyiminometylcamptothecin

Country Status (20)

Country Link
EP (1) EP1915132A1 (es)
JP (1) JP2009504616A (es)
KR (1) KR20080034989A (es)
CN (1) CN101287448A (es)
AR (1) AR055602A1 (es)
AU (1) AU2006277879A1 (es)
BR (1) BRPI0614757A2 (es)
CA (1) CA2618084A1 (es)
EC (1) ECSP088166A (es)
GT (1) GT200600364A (es)
IL (1) IL189076A0 (es)
MA (1) MA29735B1 (es)
MX (1) MX2008001965A (es)
NO (1) NO20081213L (es)
PE (1) PE20070232A1 (es)
RU (1) RU2008108885A (es)
TN (1) TNSN08062A1 (es)
TW (1) TW200800195A (es)
WO (1) WO2007017514A1 (es)
ZA (1) ZA200800726B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
RU2008108885A (ru) 2009-09-20
TW200800195A (en) 2008-01-01
IL189076A0 (en) 2008-08-07
MA29735B1 (fr) 2008-09-01
WO2007017514A1 (en) 2007-02-15
MX2008001965A (es) 2008-03-26
KR20080034989A (ko) 2008-04-22
TNSN08062A1 (en) 2009-07-14
BRPI0614757A2 (pt) 2011-04-12
CA2618084A1 (en) 2007-02-15
JP2009504616A (ja) 2009-02-05
ZA200800726B (en) 2009-08-26
AU2006277879A1 (en) 2007-02-15
AR055602A1 (es) 2007-08-29
GT200600364A (es) 2007-03-19
EP1915132A1 (en) 2008-04-30
ECSP088166A (es) 2008-03-26
CN101287448A (zh) 2008-10-15
PE20070232A1 (es) 2007-04-09

Similar Documents

Publication Publication Date Title
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
NO20072258L (no) Farmasøytiske sammensetninger omfattende et camptothecinderivat
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20081636L (no) FAP - inhibitorer
BRPI0915084B8 (pt) composto, e, composição farmacêutica
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
HN2008000130A (es) Derivados de isoquinolona sustituidos con piperidinilo en calida de inhibidores de rho-quinasa
NO20090628L (no) Pyridizinon derivativater
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
NO20090434L (no) Heteroarylforbindelser anvendbare som inhibitorer av E1-aktiverende enzymer
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
EA201201550A1 (ru) Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
MX2008008470A (es) Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application